Healthcare

Inflazome gets series B funding influx
Novartis Venture Fund returned to reinvest in inflammatory disease drug developer Inflazome as part of its $45.6m series B round.
Vapotherm turns up final IPO size
The Kaiser Permanente-backed medical device producer upscaled its initial public offering to $64.4m after the underwriters took up the over-allotment option.
Novartis and Clal help inject $40m into Cadent
Novartis and Access Industries unit Clal Biotechnology Industries both took part in the neurological disorder drug developer's series B round.
Burr burrows out of Humana
Busy Burr has moved on from her position as head of corporate venturing unit Humana Health Ventures as Humana reorganises its VC stakes.
Camel-IDS calls in $42m
Vrije Universiteit Brussel’s Camel-IDS collected funding from investors including Novo for a radiation-based oncology platform that will initially target Her2-positive brain metastatic breast cancer.
Ribometrix rips $30m in Merck-led round
Merck Group's M Ventures unit led the RNA therapy startup's series A round, which featured Amgen, Illumina, AbbVie and Mitsubishi Tanabe Pharma.
NextCure looks forward with $93m
Strategic partner Eli Lilly invested $15m while Pfizer, Ping An Ventures and Taiho Ventures also contributed to the immunotherapy developer's series B round.
Kymera reels in $65m
Pfizer Ventures and 6 Dimensions Capital joined Merck & Co, Sanofi, Eli Lilly and Amgen in Kymera's series B round, taking the protein degradation drug developer's total funding to more than $95m.

Other News

Vapotherm inhales $56m in IPO
Kaiser Permanente-backed respiratory device provider Vapotherm floated at the bottom of its range but raised $56m in its initial public offering.
Aegea adds $17m to funding pool
The Medtronic and BioMed Realty-backed medical device developer bumped its overall funding to $113m with a round led by Solas BioVentures.
Cochlear rests funding in Nyxoah's account
The sleep disorder treatment developer has raised an additional $17.1m in a round led by medical device maker Cochlear.
Roivant revs up with $200m
Existing investors SoftBank Vision Fund and Dexxon both returned for a $200m round that will help drug developer Roivant Sciences expand its range of subsidiaries.
Moderna models $500m IPO filing
Merck & Co, AstraZeneca and Alexion are all in line for exits after Moderna Therapeutics, valued at $7.5bn earlier this year, filed for its initial public offering.
Corporates exit as HealthLoop joins GetWellNetwork
GetWellNetwork has bolstered its digital experience by acquiring the patient engagement platform, giving exits to iCarbonX, Lafayette General and Summation Health Ventures.

Editor's Picks

Moderna models $500m IPO filing
Merck & Co, AstraZeneca and Alexion are all in line for exits after Moderna Therapeutics, valued at $7.5bn earlier this year, filed for its initial public offering.
Orchard IPO bears $200m of fruit
GSK, Sphera Global and Medison-backed gene therapy developer Orchard Therapeutics raised $200m in an offering that could possibly close at $230m.
Innovent enters public markets with $421m IPO
Legend Holdings, Eli Lilly, Ping An, China Life and Taikang-backed Innovent Biologics priced its shares near the top of the range of to raise $421m.
Innovent advances closer to $500m IPO
Legend Holdings, Eli Lilly, Ping An, China Life and Taikang Insurance are in line for exits as Innovent Biologics gears up for an initial public offering sized at $400m to $500m.
test reg

Login